Finally, Liraglutide, a glucagon-like peptide-1 receptor agonist, though not formally studied for treatment of obesity in patients with cirrhosis, does not need dose adjustment, and could be a useful tool to treat obesity in patients with cirrhosis, but more evidence is needed [38]. The gene discussed is GLP1R; the disease is obesity disorder.